Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Wahn, V; Aberer, W; Eberl, W; Fasshauer, M; Kuhne, T; Kurnik, K; Magerl, M; Meyer-Olson, D; Martinez-Saguer, I; Spath, P; Staubach-Renz, P; Kreuz, W; .
Hereditary angioedema (HAE) in children and adolescents. Consensus on therapeutic strategies.
MONATSSCHR KINDERHEILK. 2012; 160(8): 774-781.
Web of Science FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Aberer Werner
Altmetrics:

Dimensions Citations:
Plum Analytics:

Abstract:
Hereditary angioedema due to C1-inhibitor deficiency (HAE-C1-INH) is a rare disease that usually presents during childhood or adolescence with intermittent episodes of potentially life-threatening angioedema. Diagnosis as early as possible is important to avoid ineffective therapies and to properly treat the edema. At a consensus meeting in June 2011, pediatricians and dermatologists from Germany, Austria and Switzerland reviewed the literature, including published international consensus recommendations for HAE therapy across all age groups. These recommendations cannot be unconditionally adopted for pediatric patients in German-speaking countries given the current approval status of drugs. This article provides an overview and discusses the drugs available for HAE therapy, their approval status and study results obtained in adults and pediatric patients. Recommendations for appropriate treatment strategies in the management of HAE in pediatric patients in German-speaking countries are provided. Currently, plasma-derived C1 inhibitor concentrate is the best licensed option for treatment of acute HAE-C1-INH attacks in pediatric patients in German-speaking countries, as well as for short-term and long-term prophylaxis.

Find related publications in this database (Keywords)
C1-inhibitor
C1 esterase inhibitor
Hereditary angioedema
Consensus
Pediatrics
© Meduni Graz Impressum